Myeloproliferative Neoplasms

The FDA has approved the JAK1/2 inhibitor ruxolitinib as treatment for patients with polycythemia vera who are resistant or intolerant to hydroxyurea

The FDA has assigned a priority review designation to the JAK1/2 inhibitor ruxolitinib as treatment for patients with polycythemia vera who are resistant or intolerant to hydroxyurea

In the first pivotal phase III study of a Janus-associated kinase (JAK) inhibitor for the treatment of polycythemia vera (PV), ruxolitinib (Jakafi) was superior to best available therapy (BAT) in maintaining control of hematocrit without the need for phlebotomy and in reducing spleen size in patients with an inadequate response to or intolerance of hydroxyurea.

Rami S. Komrokji, MD, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses an analysis of pacritinib for the treatment of myelofibrosis.

Ruxolitinib, a JAK1/2 inhibitor, is the first treatment to demonstrate efficacy in a phase III trial for patients with polycythemia vera (PV), a chronic, incurable blood cancer with limited treatment options

Ayalew Tefferi, MD, hematologist, Mayo Clinic, Rochester, Minnesota, discusses the toxicity of imetelstat in patients with myelofibrosis.

Imetelstat, a telomerase inhibitor, has demonstrated significant activity in myelofibrosis, including complete responses.

Updates on new dosing strategies, formulations, and other information on treatments for patients with non-Hodgkin lymphoma, indolent B-cell non-Hodgkin lymphoma, and myelofibrosis.

The strategy of targeting aberrant signaling in the JAK pathway appears promising thus far for SAR302503, an oral agent in development for the treatment of myelofibrosis.

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, describes three phase II and phase III trials in myelofibrosis.

Richard T. Silver, MD, Professor of Medicine, Director, Leukemia and Myleoproliferative Center, New York Presbyterian-Weill Cornell Medical Center, discusses the use hydroxyurea and interferons in myeloproliferative neoplasms.

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses the long-term experience from the COMFORT-I and COMFORT-II trials in myelofibrosis.

Patients with the rare form of blood cancer polycythemia vera whose hematocrit levels hover between 45% and 50% have a four-fold higher incidence of thrombotic complications.

Richard T. Silver, MD, Professor of Medicine, Director, Leukemia and Myleoproliferative Center, New York Presbyterian-Weill Cornell Medical Center, discusses the use of interferons in myeloproliferative neoplasms.

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses the use of JAK2 inhibitors in patients with myelofibrosis.

Tal Zaks, MD, PhD, Sanofi Oncology, details a phase II randomized study of the JAK2 inhibitor SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis (MF), post-polycythemia vera MF, or post-essential thrombocythemia MF.

Francisco Cervantes, MD, PhD, Hospital Clinic, IDIBAPS, Barcelona, Spain, discusses the initial and long-term findings of the COMFORT-II trial of ruxolitib for the treatment of myelofibrosis.

Tiziano Barbui, MD, USC Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy, on hematocrit (HCT) levels in patients with polycythemia vera (PV).

Dr. Ruben Mesa, from Mayo Clinic, Arizona, Discusses the COMFORT Ruxolitinib Trials

Dr. Ruben Mesa from the Mayo Clinic in Arizona Discusses JAK Inhibitors for Myelofibrosis

The FDA approved ruxolitinib (Jakafi) as the first drug to specifically treat patients with myelofibrosis, a bone marrow disease.

Treating myelofibrosis with the investigational JAK inhibitor ruxolitinib holds promise.